[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100129083":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":68,"collaborators":43,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":43,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":43,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":96,"whyStopped":43,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GnRH agonist","EXPERIMENTAL","3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.",[13],"Drug: GnRH agonist",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","ACTIVE_COMPARATOR","250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.",[19],"Drug: Control",[21,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation",[9],[26,27,28],"Ovidrel","Zoladex","Gonal",{"type":22,"name":15,"description":30,"armGroupLabels":31,"otherNames":32},"250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation",[15],[27,26,28],[34],{"name":35,"affiliation":36,"role":37},"Paulo Serafini, PhD","Gynecology of Faculty of Medicine of University of SãoPaulo (Disciplina de Ginecologia da Faculdade de Medicina da Universidade de São Paulo)","STUDY_CHAIR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Cláudia M Gomes, MD","CONTACT","551130596122",null,"cgomes@huntington.com.br",{"name":46,"role":41,"phone":42,"phoneExt":43,"email":47},"André M Rocha, PhD","arocha@huntington.com.br",[49],{"facility":50,"status":51,"city":52,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Assisted Reproduction Center \"Governor Mário Covas\" of the Faculty of Medicine of the University of São Paulo","RECRUITING","São Paulo","05403000","Brazil","BR",{"type":57,"coordinates":58},"Point",[59,60],-46.63611,-23.5475,{"lat":60,"lon":59},[63,66],{"name":64,"role":41,"phone":65,"phoneExt":43,"email":44},"Cláudia Gomes, MD","551176569373",{"name":64,"role":67,"phone":43,"phoneExt":43,"email":43},"PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":69,"oldOrganization":70},"Cláudia Messias Gomes","Gynecology of Faculty of Medicine of the University of SãoPaulo (Disciplina de Ginecologia da Faculdade de Medicina da Universidade de São Paulo)","100129083","phase-3-evaluation-of-the-luteolytic-effect-of-a-gonadotropin-releasing-hormone-gnrh-agonist-after-the-administration-of-human-chorionic-gonadotropin-hcg-in-the-initial-follicular-phase-a-its-influence-on-the-prognosis-of-in-vitro-fertilization-treatment-100129083",false,"NCT00948805","Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment","Inclusion Criteria:\n\n* age \\>21 and \\\u003C 38 years old\n* polycystic ovarian syndrome\n* risk for ovarian hyperstimulation syndrome\n\nExclusion Criteria:\n\n* recurrent abortion\n* endometriosis\n* more than 3 IVF failures\n* use of oral contraceptive pills in the preceding 3 months\n* low response to gonadotropins",true,"FEMALE","21 Years","38 Years",{"count":82,"type":83},25,"ESTIMATED","INTERVENTIONAL",[86],"PHASE3","This study was designed to evaluate the ability of gonadotropin releasing hormone (GnRh) agonist to prevent the rise of progesterone during controlled ovarian stimulation for in vitro fertilization (IVF) after the administration of human Chorionic Gonadotropin (hCG) on the first day of menses.",[89],"Infertility",[91,92,93,94,95],"corpus luteum rescue","Gonadotropin Releasing Hormone (GnRH agonist)","human Chorionic Gonadotropin (hCG)","infertility","pregnancy rate","UNKNOWN","2009-07-28",{"date":99,"type":83},"2009-07-29",{"date":101,"type":43},"2009-01",{"date":103,"type":83},"2010-07",{"name":5,"class":6},1]